Pharma-Bio Serv, Inc. (OTCMKTS:PBSV – Free Report) – Analysts at Zacks Small Cap lowered their FY2024 EPS estimates for shares of Pharma-Bio Serv in a report released on Monday, June 17th. Zacks Small Cap analyst B. Sorensen now expects that the company will earn $0.04 per share for the year, down from their previous estimate of $0.08. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.08 per share.
Pharma-Bio Serv Price Performance
Shares of OTCMKTS:PBSV opened at $0.53 on Wednesday. The firm’s 50 day simple moving average is $0.70 and its 200-day simple moving average is $0.86. Pharma-Bio Serv has a one year low of $0.52 and a one year high of $1.10.
About Pharma-Bio Serv
Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.
Further Reading
- Five stocks we like better than Pharma-Bio Serv
- What Are Dividend Contenders? Investing in Dividend Contenders
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Using the MarketBeat Stock Split Calculator
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- 3 Fintech Stocks With Good 2021 Prospects
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Pharma-Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma-Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.